Stryker (NYSE: SYK) reported Q4 EPS of $1.56, $0.01 better than the analyst estimate of $1.55. Revenue for the quarter came in at $2.7 billion versus the consensus estimate of $2.71 billion.

GUIDANCE:

Stryker sees Q1 2016 EPS of $1.17-$1.22, versus the consensus of $1.24.

Stryker sees FY2016 EPS of $5.50-$5.70, versus the consensus of $5.59.

"With 2015 organic sales growth of 6.1%, bolstered by a strong fourth quarter increase of 6.4%, our top line results came in above our initial guidance," said Kevin A. Lobo, Chairman and Chief Executive Officer. "This performance reflects the strength of our diversified revenue model, a commitment to innovation and the competitive advantage of our sales and marketing organizations. Our full year adjusted diluted EPS also exceeded our initial expectation, underscoring our commitment to delivering sales growth at the high end of med tech and leveraged earnings gains. With these results and the current momentum across our businesses, we feel well positioned heading into 2016."

For earnings history and earnings-related data on Stryker (SYK) click here.